v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue $ 0 $ 1,017,000 $ 0
Operating expenses:      
Research and development 17,861,000 11,546,000 13,595,000
General and administrative 14,947,000 13,651,000 11,907,000
Total operating expenses 32,808,000 25,197,000 25,502,000
Operating loss (32,808,000) (24,180,000) (25,502,000)
Interest income 1,870,000 1,565,000 472,000
Interest expense (6,000) 0 (13,000)
Loss before income taxes and noncontrolling interest (31,080,000) (22,605,000) (25,966,000)
Income tax provision 0 100,000 0
Net loss before noncontrolling interest (31,080,000) (22,705,000) (25,966,000)
Net loss attributable to noncontrolling interest (4,106,000) (4,243,000) (5,716,000)
Net loss attributable to vTv Therapeutics Inc. (26,974,000) (18,462,000) (20,250,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders (26,974,000) (18,462,000) (20,250,000)
Nonrelated Party      
Operating expenses:      
Other (expense) income, net (109,000) 160,000 (1,497,000)
Related Party      
Operating expenses:      
Other (expense) income, net $ (27,000) $ (150,000) $ 574,000
Class A Common Stock      
Operating expenses:      
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) $ (3.20) $ (3.20) $ (9.71)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) $ (3.20) $ (3.20) $ (9.71)
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) 8,423,632 5,771,052 2,084,973
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) 8,423,632 5,771,052 2,084,973